REFERENCES

George Wells; Doug Coyle; Chris Cameron; Sabine Steiner; Kathryn Coyle; Shannon Kelly; Anthony Tang; Jeff Healey; Shu-Ching Hsieh; Judith van Berkom

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Wells G, Coyle D, Cameron C, et al. Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 Apr 9.

Cover of Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation

Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet].

Show details

Contents

< PrevNext >

REFERENCES

1.: Heart and Stroke Foundation of Canada [Internet]. Ottawa: Heart and Stroke Foundation of Canada. 2009 stroke report card - full report. 2009. [cited 2012 Jan 10]. Available from: http://www.heartandstroke.com/site/apps/nlnet/content2.aspx?c=ikIQLcMWJtE&b=4955951&ct=7085089.
2.: Laupacis A, Cuddy TE. Prognosis of individuals with atrial fibrillation. Can J Cardiol. 1996 Jan;12(Suppl A):14A–16A. [PubMed: 8597995]
3.: Yadav A, Cheinman M. Atrial fibrillation in the elderly. Am J Geriatr Cardiol. 2003;12:49–56. [PubMed: 12502916]
4.: Go AS. The epidemiology of atrial fibrillation in elderly persons: the tip of the iceberg. Am J Geriatr Cardiol. 2005 Mar;14(2):56–61. [PubMed: 15785146]
5.: Hankey GJ, editor. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs? Curr Opin Neurol. Feb, 2010. pp. 65–72. [PubMed: 19949330]
6.: Savelieva I, Bajpai A, Camm AJ. Stroke in atrial fibrillation: update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices. Ann Med. 2007;39(5):371–391. [PubMed: 17701479]
7.: Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [Internet]. West Sussex (UK): John Wiley & Sons Ltd; 2011. [cited 2012 Jan 10]. Available from: www.cochrane-handbook.org.
8.: Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada [Internet]. 3rd ed. Ottawa: CADTH; 2006. [cited 2012 Mar 14]. Available from: http://cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf.
9.: Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139–1151. [PubMed: 19717844]
10.: Ezekowitz MD, Reilly PA, Nehmiz G, Simmers TA, Nagarakanti R, Parcham-Azad K, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9):1419–1426. [PubMed: 17950801]
11.: Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–992. [PubMed: 21870978]
12.: Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. -The ARISTOTLE-J study- Circ J. 2011;75(8):1852–1859. [PubMed: 21670542]
13.: Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–891. [PubMed: 21830957]
14.: Hart RG, Halperin JL. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001 Mar;32(3):803–808. [PubMed: 11239205]
15.: Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994 Mar 16;271(11):840–844. [PubMed: 8114238]
16.: Wolf PA, Abbot RD, Kannel W. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988. [PubMed: 1866765]
17.: Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003 Mar;22(2):118–123. [PubMed: 12629277]
18.: Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996 Oct;27(10):1760–1764. [PubMed: 8841325]
19.: Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006 Apr;27(8):949–953. [PubMed: 16527828]
20.: Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370–2375. [PubMed: 11343485]
21.: Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006 Jul 11;114(2):119–125. [PubMed: 16818816]
22.: Heart and Stroke Foundation of Canada [Internet]. Ottawa: Heart and Stroke Foundation of Canada. Statistics; 2012. [cited 2012 Mar 14]. Available from: http://www.heartandstroke.com/site/c.ikIQLcMWJtE/b.3483991/k.34A8/Statistics.htm.
23.: Canadian Institute for Health Information. Inpatient hospitalizations and average length of stay trends in Canada, 2003–04 and 2004–05 [Internet]. Ottawa: CIHI; Nov 30, 2005. [cited 2012 Mar 14]. Available from: http://secure.cihi.ca/cihiweb/products/hmdb_analysis_in_brief_e.pdf.
24.: Bruggenjurgen B, Rossnagel K, Roll S, Andersson FL, Selim D, Muller-Nordhorn J, et al. The impact of atrial fibrillation on the cost of stroke: the berlin acute stroke study. Value Health. 2007 Mar;10(2):137–143. [PubMed: 17391422]
25.: Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006 Sep;9(5):348–356. [PubMed: 16961553]
26.: Reynolds MR, Essebag V, Zimetbaum P, Cohen DJ. Healthcare resource utilization and costs associated with recurrent episodes of atrial fibrillation: the FRACTAL registry. J Cardiovasc Electrophysiol. 2007 Jun;18(6):628–333. [PMC free article: PMC1995078] [PubMed: 17451468]
27.: Stewart S, Murphy NF, Walker A, McGuire A, McMurray JJ. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004 Mar;90(3):286–292. [PMC free article: PMC1768125] [PubMed: 14966048]
28.: Kotowycz MA, Filion KB, Joza J, Dube D, Reynolds MR, Pilote L, et al. In-hospital management of atrial fibrillation: the CHADS score predicts increased cost. Can J Cardiol. 2011 Jul;27(4):506–513. [PubMed: 21546210]
29.: Luengo-Fernandez R, Gray AM, Rothwell PM. Population-based study of determinants of initial secondary care costs of acute stroke in the United Kingdom. Stroke. 2006 Oct;37(10):2579–2587. [PubMed: 16946157]
30.: Hohnloser SH, Duray GZ, Baber U, Halperin JL. Prevention of stroke in patients with atrial fibrillation: current strategies and future directions. Eur Heart J. 2008;10 Suppl F:H4–H10.
31.: Ruff CT, Braunwald E. Will warfarin ever be replaced? J Cardiovasc Pharmacol Ther. 2010 Sep;15(3):210–219. [PubMed: 20484119]
32.: Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011 Jan;27(1):74–90. [PubMed: 21329865]
33.: Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864–2870. [PubMed: 11401607]
34.: Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost. 2008 Feb;99(2):295–304. [PubMed: 18278178]
35.: Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology. 2007 Aug 7;69(6):546–554. [PubMed: 17679673]
36.: Glazer NL, Dublin S, Smith NL, French B, Jackson LA, Hrachovec JB, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007 Feb 12;167(3):246–252. [PubMed: 17296879]
37.: Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008 Jun;133(6 Suppl):546S–592S. [PubMed: 18574273]
38.: Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005 Apr;91(4):472–477. [PMC free article: PMC1768813] [PubMed: 15772203]
39.: Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007;(3):CD006186. [PubMed: 17636831]
40.: Andersen LV, Vestergaard P, Deichgraeber P, Lindholt JS, Mortensen LS, Frost L. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart. 2008 Dec;94(12):1607–1613. [PubMed: 18208828]
41.: Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857–867. [PubMed: 17577005]
42.: Humphries KH, Jackevicius C, Gong Y, Svensen L, Cox J, Tu JV, et al. Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can J Cardiol. 2004 Jul;20(9):869–876. [PubMed: 15266356]
43.: Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J. 2011 Aug;32(16):1968–1976. 1976a. [PubMed: 21421599]
44.: Ahrens I, Lip GY, Peter K. New oral anticoagulant drugs in cardiovascular disease. Thromb Haemost. 2010 Jul;104(1):49–60. [PubMed: 20539909]
45.: Ansell J. Warfarin versus new agents: interpreting the data. Hematology Am Soc Hematol Educ Program. 2010;2010:221–228. [PubMed: 21239798]
46.: Schirmer SH, Baumhakel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, et al. Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol. 2010 Dec 14;56(25):2067–2076. [PubMed: 21144965]
47.: Eikelboom JW, Weitz JI. New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty. BMJ. 2011;342:c7270. [PubMed: 21245113]
48.: Eriksson BI, Quinlan DJ, Eikelboom JW. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011 Feb 18;62:41–57. [PubMed: 21226611]
49.: Xarelto® (rivaroxaban tablet) 10 mg, 15 mg and 20 mg [product monograph] [Internet]. Toronto: Bayer Inc; 2012. [cited 2012 Feb 13]. Available from: http://www.bayer.ca/files/XARELTO-PM-ENG-13FEB2012-145763.pdf?#.
50.: Teitelbaum JS, von Kummer R, Gjesdal K, Kristinsson A, Gahn G, Albers GW. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation. Can J Neurol Sci. 2008 May;35(2):160–165. [PubMed: 18574928]
51.: Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011 Mar 15;123(10):1144–1150. [PubMed: 21321155]
52.: Eliquis (apixaban). 2.5 mg tablets [product monograph] [Internet]. Kirkland (QC): Pfizer Canada; 2011. [cited 2012 Feb 13]. Available from: http://www.bmscanada.ca/static/products/en/pm_pdf/Eliquis_E_PM_13%20Dec%202011_APP_CLN.pdf.
53.: Pradax™ (dabigatran etexilate capsules) 75 mg, 110 mg and 150 mg [product monograph]. Burlington (ON): Boehringer Ingelheim Canada Ltd; 2011.
54.: Sorensen SV, Kansal AR, Connolly S, Peng S, Linnehan J, Bradley-Kennedy C, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Thromb Haemost. 2011 May;105(5):908–919. [PubMed: 21431243]
55.: Keisu M, Andersson TB. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010;(196):407–418. [PubMed: 20020269]
56.: Freeman JV, Zhu RP, Owens DK, Garber AM, Hutton DW, Go AS, et al. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2004 Jan 11;154(1):1–11. [PubMed: 21041570]
57.: Freeman JV, Turakhia MP. Dabigatran compared with warfarin for stroke prevention in atrial fibrillation. Ann Intern Med. 2011;154(8):570–571. [PubMed: 21502658]
58.: Pink J, Lane S, Pirmohamed M, Hughes DA. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. BMJ. 2011;343:d6333. [PMC free article: PMC3204867] [PubMed: 22042753]
59.: Shah SV, Gage BF. Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation. Circulation. 2011 Jun 7;123(22):2562–2570. [PubMed: 21606397]
60.: Kamel H, Johnston SC, Easton JD, Kim AS. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke. 2012 Mar;43(3):881–883. [PubMed: 22308255]
61.: National Institute for Health and Clinical Excellence. Atrial fibrillation - dabigatran etexilate: ERG review of the manufacturer's resubmission [Internet]. London (UK) : NICE; Nov 1, 2011. [cited 2012 Mar 14]. Available from: http://guidance.nice.org.uk/TA/Wave21/10/FAD/ERGReviewOfResubmission/pdf/English.
62.: Husten L. Decision on apixaban (Eliquis) pushed back by three months [Internet]. New York: Forbes.com; Feb 29, 2012. [cited 2012 Mar 14]. Available from: http://www.forbes.com/sites/larryhusten/2012/02/29/decision-on-apixaban-eliquis-pushed-back-by-three-months/
63.: National Institute for Health and Clinical Excellence. Atrial fibrillation - dabigatran etexilate: final appraisal determination [Internet]. London (UK): NICE; Jan 10, 2011. [cited 2011 Sep 12]. Available from: http://guidance.nice.org.uk/TA/Wave21/10/FAD.
64.: National Institute for Health and Clinical Excellence. Atrial fibrillation (stroke prevention) - rivaroxaban: appraisal consulation document [Internet]. London (UK): NICE; Sep 12, 2011. [cited 2002 Jan 10]. Available from: http://guidance.nice.org.uk/TA/Wave24/18/Consultation/DraftGuidance.
65.: Assessing risk of bias in included studies. In: Higgins JPT, Altman DG, editors; Higgens JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. West Sussex (UK): John Wiley & Sons Ltd; 2008. pp. 187–242. Chapter 8.
66.: NHS Quality Improvement Scotland (NHS QIS). SIGN 50: A guideline developer's handbook. Edinburgh: Scottish Intercollegiate Guidelines Network; Nov, 2011. [cited 2012 Mar 16]. Available from: http://www.sign.ac.uk/pdf/sign50.pdf.
67.: Dias S, Welton NJ, Sutton AJ, Ades A. NICE DSU technical support document 2: a generalised linear modelling framework for pairwise and network meta-analysis of randomised controlled trials [Internet]. Sheffield (UK): Decision Support Unit, ScHARR, University of Sheffield; Aug, 2011. [cited 2012 Mar 14]. Available from: http://www.nicedsu.org.uk/TSD2%20ES%20-%2005_05_11_FINAL_updated%20Aug2011.pdf. [PubMed: 27466657]
68.: Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007 Nov 15;357(20):2001–2015. [PubMed: 17982182]
69.: Schulman S, Crowther MA. How I anticoagulate in 2012, new and old anticoagulant agents, and when and how to switch. Blood. 2012 Feb 1 Epub ahead of print. [PubMed: 22302737]
70.: Dias S, Welton N, Sutton A, Ades A. NICE DSU technical support document 3: heterogeneity: subgroups, meta-regression, bias and bias-adjustment [Internet]. Sheffield (UK): Decision Support Unit, ScHARR, University of Sheffield; Sep, 2011. Available from: http://www.nicedsu.org.uk/TSD3%20Heterogeneity_final%20report_docx.pdf. [PMC free article: PMC3704206] [PubMed: 23804507]
71.: Cooper NJ, Sutton AJ, Morris D, Ades AE, Welton NJ. Addressing between-study heterogeneity and inconsistency in mixed treatment comparisons: application to stroke prevention treatments in individuals with non-rheumatic atrial fibrillation. Stat Med. 2009;28(14):1861–1881. [PubMed: 19399825]
72.: Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS user manual [Internet]. Version 1.4. Cambridge (UK): Insitutue of Public Health, MRC Biostatistics Unit; Jan, 2003. [cited 2012 Mar 14]. Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/manual14.pdf.
73.: Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009 Oct;62(10):1006–1012. [PubMed: 19631508]
74.: Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L. Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med. 2010 Nov 4;363(19):1875–1876. [PubMed: 21047252]
75.: Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011 May 16;123(21):2363–2372. [PubMed: 21576658]
76.: Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, et al. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010;122(22):2246–2253. [PubMed: 21147728]
77.: Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J. 2011 Oct;32(19):2387–2394. [PubMed: 21873708]
78.: Mahaffey K, Fox KAA. Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrilation - ROCKET AF [Internet]. Slides presented at: American Heart Association (AHA) Scientific Sessions 2010; 2010 Nov 13–17; Chicago, IL. 2010. [cited 2012 Mar 14]. Available from: http://my.americanheart.org/idc/groups/ahamahpublic/@wcm/@sop/@scon/documents/downloadable/ucm_426788.pdf.
79.: US Food and Drug Administration. Briefing information for the September 20, 2010 meeting of the Cardiovascular and Renal Drugs Advisory Committee [Internet]. Sliver Spring (MD): FDA; 2010. [cited 2012 Mar 16]. Clinical review: Pradaxa (dabigatran). NDA 022-512. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM247244.pdf.
80.: US Food and Drug Administration. FDA draft briefing document for the Cardiovascular and Renal Drugs Advisory Committee (CRDAC): Xarelto® (rivaroxaban) tablets [Internet]. Silver spring (MD): FDA; 2011. [cited 2011 Dec 9]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm270796.pdf.
81.: Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med. 2011 Nov 15;155(10):660–667. W204. [PubMed: 22084332]
82.: Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975–983. [PubMed: 20801496]
83.: Wallentin L. Efficacy and safety of apixaban compared with warfarin at different levels of INR control for stroke prevention in atrial fibrillation [Internet]. Slides presented at: European Society of Cardiology (ESC) Congress 2011; 2011 Aug 27–31; Paris, France. [cited 2012 Mar 14]. Available from: http://spo.escardio.org/eslides/view.aspx?eevtid=48&fp=1157.
84.: Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992 Jan 1;116(1):78–84. [PubMed: 1530753]
85.: Sun X, Briel M, Walter SD, Guyatt GH. Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ. 2010;340:c117. [PubMed: 20354011]
86.: Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000 May;17(5):479–500. [PubMed: 10977389]
87.: Carter AM, Catto AJ, Mansfield MW, Bamford JM, Grant PJ. Predictive variables for mortality after acute ischemic stroke. Stroke. 2007 Jun;38(6):1873–1880. [PubMed: 17446429]
88.: Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263–272. [PubMed: 19762550]
89.: Cupples LA, Gagnon DR, Wong ND, Ostfeld AM, Kannel WB. Preexisting cardiovascular conditions and long-term prognosis after initial myocardial infarction: the Framingham Study. Am Heart J. 1993 Mar;125(3):863–872. [PubMed: 8438716]
90.: Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093–1100. [PubMed: 20299623]
91.: Dennis MS, Burn JP, Sandercock PA, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993 Jun;24(6):796–800. [PubMed: 8506550]
92.: Wyse DG, Love JC, Yao Q, Carlson MD, Cassidy P, Greene LH, et al. Atrial fibrillation: a risk factor for increased mortality--an AVID registry analysis. J Interv Card Electrophysiol. 2001 Sep;5(3):267–273. [PubMed: 11500581]
93.: Sullivan PW, Arant TW, Ellis SL, Ulrich H. The cost effectiveness of anticoagulation management services for patients with atrial fibrillation and at high risk of stroke in the US. Pharmacoeconomics. 2006;24(10):1021–1033. [PubMed: 17002484]
94.: Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med. 1996 Sep 9;156(16):1829–1836. [PubMed: 8790077]
95.: Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005 Jul;43(7):736–749. [PubMed: 15970790]
96.: Gould MK, Dembitzer AD, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999 May 18;130(10):789–799. [PubMed: 10366368]
97.: Bank of Canada. Inflation calculator [Internet]. Ottawa: Bank of Canada; 2012. [cited 2012 Mar 14]. Available from: http://www.bankofcanada.ca/rates/related/inflation-calculator/
98.: Ontario Ministry of Health and Long-Term Care. Ontario drug benefit formulary/comparative drug index [Internet]. Toronto: The Ministry; 2011. [cited 2012 Jan 10]. Available from: https://www.healthinfo.moh.gov.on.ca/formulary/index.jsp.
99.: Schulman S, Anderson DR, Bungard TJ, Jaeger T, Kahn SR, Wells P, et al. Direct and indirect costs of management of long-term warfarin therapy in Canada. J Thromb Haemost. 2010 Oct;8(10):2192–2200. [PubMed: 20663051]
100.: Ontario Case Costing Initiative [Internet]. Toronto: OCCI; Jun, 2011. [cited 2012 Jan 20]. Available from: http://www.occp.com.
101.: Goeree R, Blackhouse G, Petrovic R, Salama S. Cost of stroke in Canada: a 1-year prospective study. J Med Econ. 2005;8:147–167.
102.: Goeree R, Lim ME, Hopkins R, Blackhouse G, Tarride J, Xie F, et al. Prevalence, total and excess costs of diabetes and related complications in Ontario, Canada. Can J Diabetes. 2009;33(1):35–45.
103.: Regier DA, Sunderji R, Lynd LD, Gin K, Marra CA. Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy. CMAJ. 2006 Jun 20;174(13):1847–1852. [PMC free article: PMC1475919] [PubMed: 16785459]
104.: Medical Advisory Secretariat. Point-of-care international normalized ratio (INR) monitoring devices for patients on long-term oral anticoagulation therapy: an evidence-based analysis. Ontario Health Technol Assess Series [Internet]. 2009. [cited 2012 Mar 14]. Available from: http://www.health.gov.on.ca/english/providers/program/mas/tech/reviews/pdf/rev_poc_20090928.pdf. [PMC free article: PMC3377545] [PubMed: 23074516]

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial- NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK169823

Contents

< PrevNext >

PubReader
Print View
Cite this Page
Wells G, Coyle D, Cameron C, et al. Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2012 Apr 9. REFERENCES.
PDF version of this title (4.9M)

Other titles in this collection

CADTH Therapeutic Reviews

Related information

PMC
PubMed Central citations
PubMed
Links to PubMed

Recent Activity

Clear Turn Off Turn On

REFERENCES - Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagu...
REFERENCES - Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation
Literature Search Strategy - Safety, Effectiveness, and Cost-Effectiveness of Ne...
Literature Search Strategy - Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Bookshelf

Safety, Effectiveness, and Cost-Effectiveness of New Oral Anticoagulants Compared with Warfarin in Preventing Stroke and Other Cardiovascular Events in Patients with Atrial Fibrillation [Internet].

REFERENCES

Views

Other titles in this collection

Related information

Recent Activity